Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Generalized Pustular and Erythrodermic Psoriasis
NCT03942042Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixekizumab in generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP), sponsored by Eli Lilly and Company. Primary endpoint: Global Improvement Score Improvement at Week 20. Started Jul 2019; status: completed.
02
Drugs
ixekizumab
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on NCT03942042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942042.